Fate Therapeutics, Inc. (FATE) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Fate Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf, multiplexed-engineered, induced pluripotent stem cell (iPSC)-derived cellular immunotherapies for cancer and autoimmune diseases. The company has not yet generated revenue from product sales and relies on collaboration agreements and government grants.
Key Financial Metrics
| Metric (in thousands) | Q2 2024 (3 Months) | Q2 2023 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Collaboration Revenue | $6,772 | $933 | $8,697 | $59,913 |
| Net Loss | $(38,427) | $(52,755) | $(86,431) | $(71,636) |
| Net Loss Per Share (Basic/Diluted) | $(0.33) | $(0.54) | $(0.79) | $(0.73) |
| Operating Expenses (Total) | $51,855 | $63,498 | $104,848 | $151,070 |
| Cash and Cash Equivalents | $36,917 | $46,802 | $36,917 | $46,802 |
| Total Investments (Short & Long Term) | $315,124 | $309,558 | $315,124 | $309,558 |
| Total Liquidity (Cash + Investments) | $352,041 | $356,360 | $352,041 | $356,360 |
Note: Total liquidity includes cash, cash equivalents, short-term investments, and long-term investments.
Material Changes vs. Prior Period
- Revenue Volatility: Collaboration revenue increased significantly in Q2 2024 ($6.8M) compared to Q2 2023 ($0.9M), driven by a $5.0M clinical development milestone achieved with Ono Pharmaceutical. However, YTD revenue decreased sharply ($8.7M vs. $59.9M) due to the termination of the Janssen collaboration in 2023, which generated substantial revenue in the prior year.
- Expense Reduction: Total operating expenses decreased by approximately 18% in Q2 2024 compared to Q2 2023. Research and Development (R&D) expenses fell by $6.3M, and General and Administrative (G&A) expenses fell by $5.4M, primarily due to reduced third-party consultant costs and lower employee compensation/stock-based compensation.
- Capital Raise: In March 2024, the company completed a public offering of common stock and a private placement of pre-funded warrants, raising approximately $94.5 million in net proceeds ($74.5M from stock, $20.0M from warrants).
- Net Loss Improvement: The net loss narrowed in Q2 2024 compared to the same period in 2023, despite the YTD increase in loss, reflecting the timing of the Janssen revenue recognition in the prior year.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes existing cash, cash equivalents, and investments ($352.0 million as of June 30, 2024) are sufficient to fund projected operating requirements for at least the next twelve months.
- Development Focus: The company continues to advance its pipeline of iPSC-derived NK and T-cell product candidates. Key activities include ongoing clinical trials and manufacturing scale-up.
- Legal Proceedings:
- Shoreline Litigation: Fate is pursuing claims against Shoreline Biosciences and its founders for breach of contract and patent infringement. A trial is scheduled to begin October 21, 2024. The court recently denied defendants' motions for summary judgment, preserving Fate's claims.
- Securities Litigation: A securities class action lawsuit (Hadian v. Fate Therapeutics) regarding the Janssen collaboration termination remains pending, with a motion to dismiss currently under review. Two derivative actions are also stayed pending the outcome of the securities action.
- Risk Factors: Significant risks include the failure to obtain regulatory approval for novel iPSC technologies, manufacturing complexities, dependence on third-party suppliers, and the need for substantial additional funding to complete development. The company also faces risks related to global conflicts and economic instability.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $352 million liquidity position against the projected burn rate for the next 12-18 months, considering potential delays in clinical trials.
- Ono Collaboration: Monitor the status of the Ono Pharmaceutical collaboration, specifically the exercise of the Candidate 3 Development Option (expires September 30, 2024) and future milestone payments.
- Legal Outcomes: Track the progress of the Shoreline Biosciences litigation and the securities class action, as adverse outcomes could result in significant costs or reputational damage.
- Stock Price Milestones: Review the liability associated with the MSKCC license agreement, which includes stock price appreciation milestones totaling up to $75.0 million contingent on future stock price performance.
- Manufacturing Capabilities: Assess the company's progress in scaling internal GMP manufacturing capabilities versus reliance on third-party contract manufacturers.